Summary
Lung cancer remains a leading cause of morbidity and mortality worldwide. This review critically synthesizes recent advances on long non-coding RNAs (lncRNAs) in lung cancer. Unlike previous descriptive compilations, we provide an evidence-based analysis, distinguish preclinical from clinically validated findings (e.g., serum exosomal SNHG15, DLX6-AS1), and highlight recurring mechanistic themes (ceRNA, chromatin remodeling, m6A). We discuss inconsistencies in the literature, barriers to clinical translation (such as standardization, sample variability, and validation), and propose a roadmap for clinical integration, including how lncRNA panels could complement existing biomarkers like CYFRA21-1. A transparent literature search strategy is included.
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.